CCR6/CD196 recombinant proteins and antibodies

C-C chemokine receptor 6 (CCR6), also known as CD196, CKRL3, CMKBR6, GPR29 or STRL22, is a G protein-coupled receptor (GPCR) that belongs to the C-C chemokine receptor family. It is predominantly expressed on immune cells, especially dendritic cells, Th17 cells, and B cells. CCR6 primarily functions by binding to its ligand, CCL20 (MIP-3α), which mediates the chemotaxis of immune cells, thereby regulating immune responses and inflammatory processes. CCR6 plays a critical role in the immune system, particularly in the development of inflammatory diseases, infectious diseases, and autoimmune diseases. Research has shown that CCR6 is crucial in the immune microenvironment of various diseases, especially in chronic inflammation, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, and other autoimmune disorders.

Research targeting CCR6 has focused on blocking the interaction between CCR6 and its ligand, CCL20, to inhibit immune cell recruitment, thereby reducing inflammation and improving disease symptoms. In recent years, significant progress has been made in the development of drugs targeting CCR6, particularly in the areas of immunomodulation and anti-inflammatory therapy. In autoimmune diseases, CCR6 antagonists are considered a promising therapeutic strategy aimed at modulating immune cell function to alleviate disease progression.

Several biopharmaceutical companies are actively developing drugs targeting CCR6. Notably, many companies are focusing on the role of CCR6 in autoimmune and inflammatory diseases. For example, Novartis and Bayer are developing CCR6 antagonists for the treatment of Crohn’s disease, rheumatoid arthritis, and other chronic inflammatory diseases. Additionally, monoclonal antibodies targeting CCR6 are also being developed as part of immunotherapy, aimed at specifically inhibiting CCR6 activity to improve immune system function and alleviate immune-mediated diseases. With the continued research into the mechanisms of CCR6, more novel CCR6-targeted drugs are entering clinical stages. These drugs not only hold promise for improving the treatment of autoimmune diseases but may also offer new therapeutic options for other immune-related diseases, with significant clinical application potential.

To assist in the development of CCR6 targeted drugs, DIMA BIOTECH can now provide a series of spot products targeting CCR6, including CCR6 recombinant proteins, CCR6 full-length membrane proteins, anti-CCR6 monoclonal antibodies and biosimilar reference antibodies. At the same time, we can also provide systematic services, including protein/antibody customization services, antibody humanization, antibody affinity maturation, stable cell lines, etc. In addition, we have established a B cell seed bank targeting CCR6, which can screen out the lead antibody molecules required by customers in just 20 days.